全文获取类型
收费全文 | 996篇 |
免费 | 73篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 57篇 |
妇产科学 | 10篇 |
基础医学 | 91篇 |
口腔科学 | 29篇 |
临床医学 | 165篇 |
内科学 | 222篇 |
皮肤病学 | 12篇 |
神经病学 | 28篇 |
特种医学 | 241篇 |
外科学 | 92篇 |
综合类 | 22篇 |
预防医学 | 31篇 |
眼科学 | 7篇 |
药学 | 34篇 |
中国医学 | 5篇 |
肿瘤学 | 27篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 2篇 |
2021年 | 9篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 22篇 |
2017年 | 11篇 |
2016年 | 18篇 |
2015年 | 20篇 |
2014年 | 25篇 |
2013年 | 22篇 |
2012年 | 15篇 |
2011年 | 20篇 |
2010年 | 39篇 |
2009年 | 55篇 |
2008年 | 28篇 |
2007年 | 9篇 |
2006年 | 15篇 |
2005年 | 8篇 |
2004年 | 10篇 |
2003年 | 16篇 |
2002年 | 10篇 |
2001年 | 16篇 |
2000年 | 13篇 |
1999年 | 15篇 |
1998年 | 51篇 |
1997年 | 53篇 |
1996年 | 64篇 |
1995年 | 51篇 |
1994年 | 44篇 |
1993年 | 50篇 |
1992年 | 18篇 |
1991年 | 11篇 |
1990年 | 16篇 |
1989年 | 35篇 |
1988年 | 34篇 |
1987年 | 36篇 |
1986年 | 35篇 |
1985年 | 30篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1982年 | 23篇 |
1981年 | 15篇 |
1980年 | 9篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 13篇 |
1976年 | 12篇 |
1975年 | 15篇 |
排序方式: 共有1076条查询结果,搜索用时 31 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Roland D Chapurlat Monique Arlot Brigitte Burt-Pichat Pascale Chavassieux Jean Paul Roux Nathalie Portero-Muzy Pierre D Delmas 《Journal of bone and mineral research》2007,22(10):1502-1509
We sought whether microdamage could rise in postmenopausal osteoporotic women on long-term bisphosphonates, as suggested by recent animal studies. We found few microcracks in iliac bone biopsies, despite a marked reduction in bone turnover. INTRODUCTION: Animal studies suggest that bisphosphonates (BPs) could increase microdamage frequency in a dose-dependent manner, caused by excessively suppressed bone turnover. However, there is limited data in humans receiving BP therapeutic doses for >3 yr. MATERIALS AND METHODS: We measured microcrack frequency and histomorphometry parameters on transiliac bone biopsies in 50 postmenopausal osteoporotic women (mean age = 68 yr) who had received BP therapy (3 on intravenous pamidronate, 37 on oral alendronate, and 10 on oral risedronate) for at least 3 yr (mean treatment duration = 6.5 yr). We compared these results with transiliac bone biopsies obtained from 12 cadavers. We used bulk staining with green calcein as a fluorochrome. The microcracks were quantified in three 100-microm-thick sections using optic microscopy and were confirmed by laser confocal microscopy. Microcrack frequency (number of microcracks/mm2 of bone tissue) was compared between treated women and controls using nonparametric tests. We also explored predictors of microcrack frequency, including age, duration of BP therapy, and activation frequency. RESULTS: Among treated women, cancellous bone microcrack frequency was low (mean, 0.13 microcracks/mm2) and did not differ significantly from that observed in controls (0.05 microcracks/mm2; p = 0.59). Of note, 54% of the treated women and 58% of the controls had no observable microcracks. There was no association between microcrack frequency and the duration of BP therapy (for microcracks/mm2 and duration, Spearman r = 0.04, p = 0.80) and between patients' ages and the number of microcracks (Spearman r = -0.09, p = 0.61). Although bone remodeling parameters were suppressed in treated women, we found no relationship between microcrack density and activation frequency (Spearman r = -0.003, p = 0.99). Also, microcrack frequency was not increased in women with prevalent vertebral fracture compared with those without fractures. CONCLUSIONS: Among postmenopausal osteoporotic women on long-term BPs, microcrack frequency in the iliac bone is low, despite a marked reduction of bone turnover. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.